Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 4/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17037434 | 0.90 | RAB9A (0.43) | RAB9ASCN9AMEN1KMT2AALDH1A1 | |
| SCHEMBL3109976 | 0.79 | ROCK1 (0.60) | RAB9ADYRK1B | |
| SCHEMBL14947693 | 0.78 | GRM4 (0.43) | RAB9ACFTRDYRK1BGRM4 | |
| SCHEMBL18878391 | 0.78 | GRM4 (0.45) | CFTRDYRK1BGRM4 | |
| SCHEMBL14947692 | 0.76 | GRM4 (0.43) | CFTRDYRK1BGRM4 | |
| SCHEMBL17149799 | 0.74 | MEN1 (0.48) | MEN1KMT2A | |
| SCHEMBL20282465 | 0.73 | CFTR (0.44) | CFTRDYRK1BGRM4 | |
| SCHEMBL14947683 | 0.72 | PLK1 (0.44) | MEN1KMT2ACFTRDYRK1BGRM4 | |
| SCHEMBL20163069 | 0.72 | CFTR (0.43) | SCN9AMEN1KMT2ACFTRDYRK1B | |
| SCHEMBL30036869 | 0.72 | CFTR (0.43) | SCN9AMEN1KMT2ACFTRDYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586931-B2 | Triazolyl derivatives as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150239866-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK CANADA INC. (CA) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239866-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | SYK, BTK, TYRO3 | RAB9A 3861/4885SCN9A 3990/4885MEN1 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.